Search

Search Results

1. Multiple omics levels of chronic lymphocytic leukemia

   Chronic lymphocytic leukemia (CLL) is a lymphoproliferative malignancy characterized by the proliferation of functionally mature but incompetent B...

   Aleksander Turk, Eva Čeh, ... Tanja Kunej in Cell Death Discovery

   Article Open access 21 June 2024
   

2. “Immuno-FlowFISH”: Applications for Chronic Lymphocytic Leukemia

   Imaging flow cytometry has the capacity to bridge the gap that currently exists between the diagnostic tests that detect important phenotypic and...

   Henry Y. L. Hui, Wendy N. Erber, Kathy A. Fuller in Spectral and Imaging Cytometry

   Protocol 2023
   

3. Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia

   The tumor microenvironment (TME) plays a central role in the pathogenesis of chronic lymphocytic leukemia (CLL), contributing to disease progression...

   Gioia Boncompagni, Vanessa Tatangelo, ... Cosima T. Baldari in Cell Death & Disease

   Article Open access 15 February 2024
   

4. Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death

   Microenvironmental signals strongly influence chronic lymphocytic leukemia (CLL) cells through the activation of distinct membrane receptors, such as...

   Maria Elena Mantione, Miriam Meloni, ... Marta Muzio in Cell Death & Disease

   Article Open access 18 March 2024
   

5. A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine

   The microenvironment of chronic lymphocytic leukemia (CLL) cells in lymph nodes, spleen, and bone marrow provides survival, proliferation, and drug...

   Johanne U. Hermansen, Yan** Yin, ... Sigrid S. Skånland in Cell Death Discovery

   Article Open access 13 April 2023
   

6. The rs1001179 SNP and CpG methylation regulate catalase expression in chronic lymphocytic leukemia

   Chronic lymphocytic leukemia (CLL) is an incurable disease characterized by an extremely variable clinical course. We have recently shown that high...

   Marilisa Galasso, Elisa Dalla Pozza, ... Maria T. Scupoli in Cellular and Molecular Life Sciences

   Article Open access 16 September 2022
   

7. Aberrantly expressed Wnt5a in nurse-like cells drives resistance to Venetoclax in chronic lymphocytic leukemia

   Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of neoplastic B lymphocytes with high levels of Wnt5a in the plasma....

   Yao Guo, Hanzhong Pei, ... Yun Chen in Cell Death Discovery

   Article Open access 24 February 2022
   

8. Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax

   Chronic lymphocytic leukemia (CLL) is a hematological neoplasm of CD19-positive mature-appearing B lymphocytes. Despite the clinical success of...

   Damjan Avsec, Marja Škrlj Miklavčič, ... Irena Mlinarič-Raščan in Cell Death & Disease

   Article Open access 08 October 2022
   

9. Anti-proliferation and pro-apoptosis effects of miR-582-5p in chronic lymphocytic leukemia via targeting HNRNPA1 and suppression of NF-κB

   Background

   MicroRNAs (miRNAs) function as post-transcriptional mediators for genes involved in cancer progression, including chronic lymphocytic...

   Zengsheng Wang, Yan Li, ... Haiqing Yang in Molecular & Cellular Toxicology

   Article 01 June 2021
   

10. CLLU1 as an emerging biomarker in chronic lymphoid leukemia

    CLLU1, a disease-specific gene associated with chronic lymphoid leukemia (CLL), is located on chromosome 12q22. Previous studies considered CLLU1 to...

    Chunmeng Rong, Chenhao Liang, ... Shiwei Duan in Human Cell

    Article 20 March 2024
    

11. Nucleolar and spindle associated protein 1 enhances chemoresistance through DNA damage repair pathway in chronic lymphocytic leukemia by binding with RAD51

    Nucleolar and spindle-associated protein 1 (NUSAP1) is an essential regulator of mitotic progression, spindle assembly, and chromosome attachment....

    Yang Han, **nting Hu, ... **n Wang in Cell Death & Disease

    Article Open access 15 November 2021
    

12. Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation

    Background

    Chromosomal abnormalities and gene mutations determine the prognosis of patients with chronic lymphocytic leukemia (CLL). Genetic lesions...

    Susanne Bracher, Irene Fuhrmann, ... Anna Stengel in Molecular Biology Reports

    Article 28 September 2022
    

13. Evaluation of Bone Turnover Markers in Patients with Acute and Chronic Leukemia

    This study investigated different bone biomarkers (cross-linked carboxy-terminal telopeptide of type 1 collagen (CTX-1), pyridinoline (PYD),...

    Reem A. Al-Qaisi, Abdulnasser M. Al-Gebori, Mohammed Hadi Munshed Alosami in Indian Journal of Clinical Biochemistry

    Article 03 March 2023

14. Platelet microparticles influence gene expression and modulate biological activities of chronic myeloid leukemia cells (K562)

    Background

    The current understanding emphasizes the intricate interplay between the Leukemic cell and its environment. Platelet-derived microparticles...

    Fariba Nikravesh, Roohollah Mirzaee Khalilabadi, ... Hajar Mardani Valandani in Molecular Biology Reports

    Article 25 May 2024
    

15. Blockade of PD-1 and TIM-3 Ameliorates CD8⁺ T Cell Exhaustion in a Mouse Model of Chronic Myeloid Leukemia

    The immune system plays a pivotal role in controlling chronic myeloid leukemia (CML). CD8 ⁺ T cell exhaustion results in reduced effectiveness of T...

    Ting **, Fei Gao, Li Wang in Cell Biochemistry and Biophysics

    Article 12 July 2024
    

16. Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide

    Background

    Targeting influential factors in resistance to chemotherapy is one way to increase the effectiveness of chemotherapeutics. The nuclear...

    Atefeh Khodakarami, Mahsa Afsari Kashani, ... Farhad Jadidi-Niaragh in Cell Communication and Signaling

    Article Open access 01 August 2023
    

17. Develo** therapeutic approaches for chronic myeloid leukemia: a review

    Modern clinical therapy of chronic myeloid leukemia (CML) with TKIs is highly efficacious in most CML patients, while it is not remedial and...

    Veerandra Kumar, Jyotirmayee, Malkhey Verma in Molecular and Cellular Biochemistry

    Article 10 October 2022
    

18. BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia

    Dysregulation of the BCL-2 family is implicated in protecting chronic myeloid leukemia (CML) cells from intracellular damage and BCR::ABL1-inhibition...

    Narissa Parry, Caroline Busch, ... Mhairi Copland in Cell Death Discovery

    Article Open access 15 November 2022
    

19. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells

    Signaling via the B-cell receptor (BCR) is a key driver and therapeutic target in chronic lymphocytic leukemia (CLL). BCR stimulation of CLL cells...

    Sarah Wilmore, Karly-Rai Rogers-Broadway, ... Alison Yeomans in Cellular and Molecular Life Sciences

    Article Open access 16 August 2021
    

20. Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia

    Chronic lymphocytic leukemia (CLL) has a complex pattern of driver mutations and much of its clinical diversity remains unexplained. We devised a...

    Junyan Lu, Ester Cannizzaro, ... Wolfgang Huber in Nature Cancer

    Article 01 July 2021